{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T23:07:22Z","timestamp":1768259242927,"version":"3.49.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T00:00:00Z","timestamp":1676592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T00:00:00Z","timestamp":1676592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s00392-023-02172-w","type":"journal-article","created":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T10:02:54Z","timestamp":1676628174000},"page":"1067-1076","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["KCCQ total symptom score, clinical outcome measures, and adverse events associated with omecamtiv mecarbil for heart failure with reduced ejection fraction: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0124-9513","authenticated-orcid":false,"given":"Ramzi","family":"Ibrahim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulbaril","family":"Olagunju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Terrani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chelsea","family":"Takamatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Khludenev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Preethi","family":"William","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,17]]},"reference":[{"issue":"5","key":"2172_CR1","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1001\/jama.2020.10262","volume":"324","author":"SP Murphy","year":"2020","unstructured":"Murphy SP, Ibrahim NE, Januzzi JL Jr (2020) Heart failure with reduced ejection fraction: a review. JAMA 324(5):488\u2013504","journal-title":"JAMA"},{"issue":"6023","key":"2172_CR2","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1126\/science.1200113","volume":"331","author":"FI Malik","year":"2011","unstructured":"Malik FI et al (2011) Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science 331(6023):1439\u20131443","journal-title":"Science"},{"key":"2172_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP et al (2011) The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343:d5928","journal-title":"BMJ"},{"issue":"1","key":"2172_CR4","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","volume":"12","author":"LA McGuinness","year":"2021","unstructured":"McGuinness LA, Higgins JPT (2021) Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods 12(1):55\u201361","journal-title":"Res Synth Methods"},{"issue":"9792","key":"2172_CR5","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/S0140-6736(11)61126-4","volume":"378","author":"JG Cleland","year":"2011","unstructured":"Cleland JG et al (2011) The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet 378(9792):676\u2013683","journal-title":"Lancet"},{"issue":"1","key":"2172_CR6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jchf.2014.07.009","volume":"3","author":"BH Greenberg","year":"2015","unstructured":"Greenberg BH et al (2015) Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and angina. JACC Heart Fail 3(1):22\u201329","journal-title":"JACC Heart Fail"},{"issue":"3","key":"2172_CR7","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1001\/jama.2022.11016","volume":"328","author":"GD Lewis","year":"2022","unstructured":"Lewis GD et al (2022) Effect of omecamtiv mecarbil on exercise capacity in chronic heart failure with reduced ejection fraction: the METEORIC-HF randomized clinical trial. JAMA 328(3):259\u2013269","journal-title":"JAMA"},{"issue":"2","key":"2172_CR8","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1056\/NEJMoa2025797","volume":"384","author":"JR Teerlink","year":"2021","unstructured":"Teerlink JR et al (2021) Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure. N Engl J Med 384(2):105\u2013116","journal-title":"N Engl J Med"},{"issue":"10062","key":"2172_CR9","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1016\/S0140-6736(16)32049-9","volume":"388","author":"JR Teerlink","year":"2016","unstructured":"Teerlink JR et al (2016) Chronic oral study of myosin activation to increase contractility in heart failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Lancet 388(10062):2895\u20132903","journal-title":"Lancet"},{"issue":"12","key":"2172_CR10","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.jacc.2016.01.031","volume":"67","author":"JR Teerlink","year":"2016","unstructured":"Teerlink JR et al (2016) Acute treatment with omecamtiv mecarbil to increase contractility in acute heart failure: the ATOMIC-AHF study. J Am Coll Cardiol 67(12):1444\u20131455","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"2172_CR11","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ihj.2022.03.005","volume":"74","author":"F Alqatati","year":"2022","unstructured":"Alqatati F et al (2022) Safety and efficacy of omecamtiv mecarbil for heart failure: a systematic review and meta-analysis. Indian Heart J 74(3):155\u2013162","journal-title":"Indian Heart J"},{"issue":"9","key":"2172_CR12","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1002\/ejhf.1933","volume":"22","author":"AA Voors","year":"2020","unstructured":"Voors AA et al (2020) Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial. Eur J Heart Fail 22(9):1649\u20131658","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"2172_CR13","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.121.008970","volume":"15","author":"GD Lewis","year":"2022","unstructured":"Lewis GD et al (2022) Developments in exercise capacity assessment in heart failure clinical trials and the rationale for the design of METEORIC-HF. Circ Heart Fail 15(5):e008970","journal-title":"Circ Heart Fail"},{"issue":"23","key":"2172_CR14","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1093\/eurheartj\/ehac144","volume":"43","author":"SD Solomon","year":"2022","unstructured":"Solomon SD et al (2022) Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial. Eur Heart J 43(23):2212\u20132220","journal-title":"Eur Heart J"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-023-02172-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-023-02172-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-023-02172-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T07:05:16Z","timestamp":1689836716000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-023-02172-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,17]]},"references-count":14,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["2172"],"URL":"https:\/\/doi.org\/10.1007\/s00392-023-02172-w","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,17]]},"assertion":[{"value":"18 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}